Search 

NYU Langone Medical Center is one of the nation’s premier academic medical centers. Our trifold mission to serve, teach, and discover is achieved daily through an integrated academic culture devoted to excellence in patient care, education, and research.Located in the heart of Manhattan, with additional facilities throughout the New York City area, NYU Langone consists of four hospitals:

• Tisch Hospital, our flagship acute-care facility
• Rusk Rehabilitation, ranked as one of the top 10 rehabilitation programs in the country by U.S. News & World Report since 1989, and recently awarded a three-year accreditation from the Commission on Accreditation of Rehabilitation Facilities  (CARF)
• Hospital for Joint Diseases, a dedicated inpatient orthopaedic hospital 
• Hassenfeld Children’s Hospital, which provides comprehensive children's health services across NYU Langone

The Department of Orthopaedic Surgery is responsible for providing the full range of adult orthopaedic services to patients at the Hospital for Joint Diseases at NYU Langone Medical Center.

This specialty hospital is dedicated solely to the treatment of orthopaedic and rheumatologic conditions. Members of the Hospital for Joint Diseases service follow the highest professional standards in evaluating and treating in-hospital patients, patients who seek treatment in the numerous clinics, and patients who visit the Hospital's Immediate Care Center, a unique facility that provides urgent orthopaedic care.

Specialties:  Oncology, Cancer Research, Cell Biology

NYU School of Medicine is one of the nation’s preeminent academic institutions. For more than 150 years, we have trained thousands of physician-scientists who have helped to shape the course of medical history and enrich the lives of countless people. Through medical education, scientific research, and patient care, we continue to demonstrate our deep, abiding commitment to improving the human condition.

The percentage of NYU graduates who are members of medical school faculties is among the highest in the nation. For most of them, an invaluable part of that training was their service at Bellevue Hospital, one of the nation’s finest municipal hospitals, where NYU physicians have provided clinical and emergency care to
New York City’s poor and immigrant populations for more than a century.

As part of a “biomedical corridor” extending from 23rd to 34th Streets along Manhattan’s East River Drive, our institution is guided by the promise of “translational medicine,” in which scientific discoveries are urgently translated into innovative treatments for patients. To create an environment worthy of rapid medical advances, we are constructing new research and clinical facilities. These state-of-the-art facilities will serve as the home for our physician-scientists who are the intellectual foundation of the School. In addition, we are recruiting a new generation of scholars and teachers who have established national and international reputations. And we are admitting some of the nation’s best and brightest students, many of whom will become tomorrow’s leaders in the medical profession.

Your focus and ours is whether NYU is the right place to pursue your medical education. We hope that this website captures the spirit of the educational enterprise at NYU, as well as the experience of studying medicine in the heart of New York City.

CARDIOVASCULAR

Dr. Mignatti's two NIH grants support the study of a novel mechanism that controls the growth of a number of cells including the cells of the blood vessels. These cells produce a protein referred to as Membrane Type 1 Matrix Metalloproteinase (MT1-MMP). MT1-MMP has the capacity of digesting structural proteins that surround the cells, an important function for new vessels to make their way into the tissues that need to be vascularized. Unlike proteins with similar functions, MT1-MMP is bound to the cell membrane, the sheath that surrounds the cell, a feature that makes it similar to other proteins - growth factor- or hormone- receptors. These proteins have the role of relaying signals from the outside to the inside of the cell when they bind their cognate growth factors or hormones. These signals regulate many cell functions, including the capacity to grow and form new vessels. MT1-MMP also binds an extracellular protein called tissue inhibitor of metalloproteinases-2 (TIMP-2). Dr. Mignatti's group discovered that MT1-MMP binding of TIMP-2 activates signals inside the cell which stimulate cell growth and movement. The current work aims to understand the mechanisms by which MT1-MMP relays signals from the outside to the inside of the cell. For this purpose the research group uses both techniques of molecular and cellular biology, and animal models engineered in the laboratory. The results of these studies can afford the development of novel drugs to control the growth of a variety of cells including those that form blood vessel.

NYU Langone Medical Center is one of the nation’s premier academic medical centers. Our trifold mission to serve, teach, and discover is achieved daily through an integrated academic culture devoted to excellence in patient care, education, and research.

Olmix is a marine biotechnology specialist providing algae-based therapeutic solutions in CNS, oncology and immunology.

AN UNIQUE INNOVATIVE SOLUTION

Olmix group has developed specific knowledge and technologies to extract and select algal molecules of interest for animal and plant health. Some of these molecules can also be beneficial for human health and one of them has been identified as a potential antidepressant for humans.                                             

We have found in algae a new antidepressant molecule which from what we know at the moment provide beneficial effects against depression without any undesirable side effect.

KEY VALUE PROPOSITION

• Efficient Natural solution
• No side effect
• Easy to produce

TARGET MARKET SEGMENTS

• Central Nervous system             
• Antidepressant
• Other applications and compounds in oncology and immunology

TARGET PARTNERS

• Co-development partners with interest in described therapeutic areas
• Investors (Corporate funds, VC...)

Backed by unique experience acquired through more than 600 clients, including the world

At the core of our innovative connection-based concept, our qualifying approach generates as much information as possible about the pharmacological behavior of a molecule. With this approach, Oncodesign aims to optimally position each molecule towards a disease indication and a patient population, in order to maximize its value.

Pharmaceutical Labs / Biotechs / Academics

Innovation: Oncodesign devises new solutions (Pharmimage)

As a not-for-profit, the goal of One Million Solutions in Health is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.

In this next year, we will be reviewing 100's of new solutions and new scientific discoveries through the Technology Evaluation Consortium™ (contact us about membership). By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way.

We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. As an example, we have had a fabulous, global response, through our sister company, to find cures and raise $100 million to support their commercialization.

We are thrilled to have you be a part of this transformative journey!